Table 1.
First Author/Year | Country (Ethnicity) | Sample Size⁎⁎ | Age (range) | F/M | HC | Cancer treatment in total cases |
NOS | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Surgery | Radiotherapy | Chemotherapy | Targeted therapy | Immunotherapy | |||||||
Yang et al., 2020 | China (Asian) | 205 | 63(56-70) | 109/96 | 22 | 4(2.0) | 9(4.4) | 31(15.1) | 12(5.9) | 4(2.0) | 8 |
Tian et al., 2020 | China (Asian) | 232 | 64(58-69) | 113/119 | 12 | 197(84.9) | 214(92.2) | 32(13.8) | 8 | ||
Liang et al., 2020 | China (Asian) | 18 | 62(56-68) | 6/12 | 1 | 1(5.6) | 0(0.0) | 2(11.1) | 2(11.1) | 1(5.6) | 8 |
Dai et al., 2020 | China (Asian) | 105 | 64(55-69) | 48/57 | 9 | 8(7.6) | 13 (12.4) | 17(16.2) | 4(3.8) | 6(5.7) | 8 |
Ali et al., 2020 | Pakistan (Asian) | 201 | 45(18–78) | 115/86 | 33 | 22(10.9) | 13(6.5) | 146(72.6) | 2(1) | 0(0.0) | 8 |
Aznab et al., 2020 | Iran (Asian) | 161 | NA | NA | 64 | NA | NA | NA | NA | NA | 6 |
Kuderer et al., 2020 | Caucasian* | 928 | 66(57-76) | 412/516 | 167 | 32(3.4) | 12(1.3) | 160(17.2) | 75(8.1) | 38(4.1) | 9 |
Lee et al., 2020 | UK (Caucasian) | 800 | 69(59-76) | 349/449 | 169 | 29(3.6) | 76(9.5) | 281(35.1) | 72(9.0) | 44(5.5) | 9 |
Russeli et al., 2020 | UK (Caucasian) | 156 | 65 | 66/90 | 28 | NA | NA | 45(55.6) | 5(6.2) | 7(8.6) | 7 |
Bhogal et al., 2021 | UK (Caucasian) | 179 | 72(61-81) | 74/105 | 52 | 39(21.8) | 34(19.0) | 117(65.4) | 8 | ||
Barlesi et al., 2020 | France (Caucasian) | 137 | 61(21-90) | 79/58 | 24 | 0(0.0) | 0(0.0) | 48(35.0) | 18(13.1) | 12(8.8) | 8 |
Albiges et al., 2020 | France (Caucasian) | 178 | 60(52-71) | 102/76 | 30 | NA | NA | NA | NA | NA | 6 |
Mehta et al., 2020 | USA (Caucasian) | 218 | 69(10-92) | 91/127 | 54 | 0(0.0) | 49(22.5) | 42(19.3) | 0(0.0) | 5(2.3) | 8 |
Elkrief et al., 2020 | Canada (Caucasian) | 252 | 73(4-95) | 125/127 | 20 | NA | NA | NA | NA | NA | 6 |
NA: Not Available; F/M: Female/Male; HC: Hematological Cancer; NOS: Newcastle-Ottawa Scale.
Europe, USA, Asia;
All cancer cases with SARS-CoV-2 Infection.